NCT00402714View on ClinicalTrials.gov

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

August 31, 2009

Conditions
Hematologic Malignancies
Interventions
PROCEDURE

extracorporeal photopheresis

Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.

DRUG

Pentostatin

pentostatin 8mg/m2 over 48 hours by continuous infusion

RADIATION

Total Body Irradiation

600cGy TBI in 3 200cGy TBI fractions

DRUG

Pentostatin

pentostatin 8mg/m2 over 48 hours by continuous infusion

RADIATION

Total Body Irradiation

600cGy TBI in 3 200cGy TBI fractions

Trial Locations (3)

78229

Methodist Hospital - Texas Transplant Institute, San Antonio

06520

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven

02111

Tufts-New England Medical Center, Boston

All Listed Sponsors
collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Yale University

OTHER

NCT00402714 - A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies | Biotech Hunter | Biotech Hunter